In a win for in­dus­try, Trump ad­min­is­tra­tion is­sues scathing re­view of Pelosi drug pric­ing bill

Pres­i­dent Don­ald Trump wants it both ways — cheap­er drugs and vig­or­ous in­no­va­tion. Ear­li­er this year, the De­moc­rats’ re­vealed their drug pric­ing bill, which is en­gi­neered to em­pow­er the HHS to ne­go­ti­ate prices for se­lect drugs. The White House has now emerged as one of its harsh­est crit­ics.

“Heavy-hand­ed gov­ern­ment in­ter­ven­tion may re­duce drug prices in the short term, but these sav­ings are not worth the long-term cost of Amer­i­can pa­tients los­ing ac­cess to new life­sav­ing treat­ments,” the Trump ad­min­is­tra­tion wrote in an analy­sis post­ed on Tues­day, pro­vid­ing a boost to the in­dus­try that has thrived in its large­ly Lais­sez-faire ecosys­tem.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER